Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3
Main Article Content
Keywords
cemiplimab
References
2. Stratigos AJ et al. Eur J Cancer. 2020;128:60–82.
3. Que SKT et al. J Am Acad Dermatol. 2018;78:237–247.
4. Burova E et al. Mol Cancer Ther. 2017;16:861–870.
5. Regeneron Pharmaceuticals, Inc and Sanofi-Aventis US LLC. LIBTAYO® [cemiplimab-rwlc] injection full US prescribing information; 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf. Accessed August 31, 2022.
6. European Medicines Agency. LIBTAYO® EPAR; 2022. Available at: https://www.ema.europa.eu/en/documents/product-information/libtayo-eparproduct-
information_en.pdf. Accessed August 31, 2022.
7. Health Canada. LIBTAYO® - Notice of compliance with conditions - qualifying notice; 2019. Available at: https://www.canada.ca/en/health-canada/services/
drugs-health-products/drug-products/notice-compliance/conditions/libtayo-noticecompliance-conditions-218718.html. Accessed August 31, 2022.
8. Ministry of Health Israel. The Israeli Drug Registry - LIBTAYO®; 2021. Available at: https://mohpublic.z6.web.core.windows.net/IsraelDrugs/Rishum01_1_1299478321.pdf. Accessed August 31, 2022.
9. Stratigos AJ et al. Eur J Cancer. 2020;128:83–102.
10. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer
(Version 2.2022); 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed August 31, 2022.
11. Rischin D et al. J Immunother Cancer. 2021;9:e002757.
12. Migden MR et al. N Engl J Med. 2018;379:341–351.
13. Migden MR et al. Lancet Oncol. 2020;21:294–305.
14. Rischin D et al. J Immunother Cancer. 2020;8:e000775.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.